Effect of carvedilol in preventing heart failure following herceptin therapy
Phase 2
- Conditions
- breast cancer.Malignant neoplasm of breastC50-C50
- Registration Number
- IRCT2014112019840N1
- Lead Sponsor
- Vice chancellor of research of Tehran university of medical scienses
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Inclusion:patients with HER2 positive breast cancer who are candidate for herceptin therapy
Exclusion: history of systolic heart failure (EF<50), history of anthracycline therapy,contraindications for beta blockers, history of coronary artery disease,symptoms of heart failure including orthopnea or PND or dyspnea on exertion
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Heart failure. Timepoint: 3 months after administration of herceptin. Method of measurement: echocardiography.
- Secondary Outcome Measures
Name Time Method